Mechanisms of estrogen protection in diabetes and metabolic disease

Hormone Molecular Biology and Clinical Investigation

Volumn 4, Issue 2, 2010, Pages 575-580

  Cignarella, Andrea ^a   Bolego, Chiara ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Diabetes; Estrogen; Inflammation; Menopausal hormone therapy; Obesity

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLUCOSE; INSULIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; DIABETES MELLITUS; DRUG MECHANISM; ESTROGEN ACTIVITY; ESTROGEN THERAPY; GLUCOSE TOLERANCE; HORMONAL THERAPY; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; MENOPAUSE; META ANALYSIS (TOPIC); METABOLIC DISORDER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 85007200685     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2010.084     Document Type: Article

References (54)

1. Shen W, Punyanitya M, Silva AM, Chen J, Gallagher D, Sardinha LB, Allison DB, Heymsfield SB. Sexual dimorphism of adipose tissue distribution across the lifespan: a cross-sectional whole-body magnetic resonance imaging study. Nutr Metab (Lond) 2009;6:17.
2. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88:2404-11.
3. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr, Razak F, Sharma AM, Anand SS, INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27, 000 participants from 52 countries: a case-control study. Lancet 2005;366:1640-9.
4. Andersson T, Söderström I, Simonyté K, Olsson T. Estrogen reduces 11b-hydroxysteroid dehydrogenase type 1 in liver and visceral, but not subcutaneous, adipose tissue in rats. Obesity 2010;18:470-5.
5. Paulsen SK, Nielsen MP, Richelsen B, Bruun JM, Flyvbjerg A, Pedersen SB. Upregulation of adipose 11-b-hydroxysteroid dehydrogenase type 1 expression in ovariectomized rats is due to obesity rather than lack of estrogen. Obesity 2008;16:731-5.
6. Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani AR. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 2001;39: 125-32.
7. Genazzani AR, Gambacciani M. Effect of climacteric transition and hormone replacement therapy on body weight and body fat distribution. Gynecol Endocrinol 2006;22:145-50.
8. Brown LM, Gent L, Davis K, Clegg DJ. Metabolic impact of sex hormones on obesity. Brain Res 2010;1350:77-85.
9. Levin ER. Plasma membrane estrogen receptors. Trends Endocrinol Metab 2009;20:477-82.
10. Mårtensson UE, Salehi SA, Windahl S, Gomez MF, Swärd K, Daszkiewicz-Nilsson J, Wendt A, Andersson N, Hellstrand P, Grände PO, Owman C, Rosen CJ, Adamo ML, Lundquist I, Rorsman P, Nilsson BO, Ohlsson C, Olde B, Leeb-Lundberg LM. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 2009;150:687-98.
11. Nedungadi TP, Clegg DJ. Sexual dimorphism in body fat distribution and risk for cardiovascular diseases. J Cardiovasc Transl Res 2009;2:321-7.
12. Puah JA, Bailey CJ. Insulinotropic effect of ovarian steroid hormones in streptozotocin diabetic female mice. Horm Metab Res 1985;17:216-8.
13. Le May C, Chu K, Hu M, Ortega CS, Simpson ER, Korach KS, Tsai MJ, Mauvais-Jarvis F. Estrogens protect pancreatic bcells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci USA 2006;103:9232-7.
14. Eckhoff DE, Smyth CA, Eckstein C, Bilbao G, Young CJ, Thompson JA, Contreras JL. Suppression of the c-Jun N-terminal kinase pathway by 17b-estradiol can preserve human islet functional mass from proinflammatory cytokine-induced destruction. Surgery 2003;134:169-79.
15. Nadal A, Rovira JM, Laribi O, Leon-Quinto T, Andreu E, Ripoll C, Soria B. Rapid insulinotropic effect of 17b-estradiol via a plasma membrane receptor. FASEB J 1998;12:1341-8.
16. Mauvais-Jarvis F. Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol Metab 2011;22:24-33.
17. Alonso-Magdalena P, Ropero AB, Carrera MP, Cederroth CR, Baquié M, Gauthier BR, Nef S, Stefani E, Nadal A. Pancreatic insulin content regulation by the estrogen receptor ERa. PLoS ONE 2008;3:e2069.
18. Ropero AB, Alonso-Magdalena P, Quesada I, Nadal A. The role of estrogen receptors in the control of energy and glucose homeostasis. Steroids 2008;73:874-9.
19. Geary N, Asarian L, Korach KS, Pfaff DW, Ogawa S. Deficits in E2-dependent control of feeding, weight gain, and cholecystokinin satiation in ER-a null mice. Endocrinology 2001;142: 4751-7.
20. Foryst-Ludwig A, Kintscher U. Metabolic impact of estrogen signalling through ERalpha and ERbeta. J Steroid Biochem Mol Biol 2010;122:74-81.
21. Cignarella A, Kratz M, Bolego C. Emerging role of estrogen in the control of cardiometabolic disease. Trends Pharmacol Sci 2010;31:183-9.
22. Ding EL. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia 2007;50:2076-84.
23. Kalyani RR, Franco M, Dobs AS, Ouyang P, Vaidya D, Bertoni A, Gapstur SM, Golden SH. The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab 2009;94:4127-35.
24. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH, Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(7 Suppl 1):s1-66.
25. Ohlsson C, Hellberg N, Parini P, Vidal O, Bohlooly-Y M, Rudling M, Lindberg MK, Warner M, Angelin B, Gustafsson JA. Obesity and disturbed lipoprotein profile in estrogen receptora- deficient male mice. Biochem Biophys Res Commun 2000; 278:640-5.
26. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptora knockout mice. Proc Natl Acad Sci USA 2000;97:12729-34.
27. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999; 20:358-417.
28. Naaz A, Zakroczymski M, Heine P, Taylor J, Saunders P, Lubahn D, Cooke PS. Effect of ovariectomy on adipose tissue of mice in the absence of estrogen receptor alpha (ERa): a potential role for estrogen receptor beta (ERb). Horm Metab Res 2002;34:758-63.
29. Andersson T, Simonyte K, Andrew R, Strand M, Burén J, Walker BR, Mattsson C, Olsson T. Tissue-specific increases in 11bhydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women. PLoS ONE 2009;4:e8475.
30. Simonyte K, Rask E, Näslund I, Angelhed JE, Lönn L, Olsson T, Mattsson C. Obesity is accompanied by disturbances in peripheral glucocorticoid metabolism and changes in FA recycling. Obesity (Silver Spring) 2009;17:1982-7.
31. Low SC, Chapman KE, Edwards CR, Wells T, Robinson IC, Seckl JR. Sexual dimorphism of hepatic 11b-hydroxysteroid dehydrogenase in the rat: the role of growth hormone patterns. J Endocrinol 1994;143:541-8.
32. Jamieson PM, Nyirenda MJ, Walker BR, Chapman KE, Seckl JR. Interactions between oestradiol and glucocorticoid regulatory effects on liver-specific glucocorticoid-inducible genes: possible evidence for a role of hepatic 11b hydroxysteroid dehydrogenase type 1. J Endocrinol 1999;160:103-9.
33. Tagawa N, Yuda R, Kubota S, Wakabayashi M, Yamaguchi Y, Kiyonaga D, Mori N, Minamitani E, Masuzaki H, Kobayashi Y. 17b-Estradiol inhibits 11b-hydroxysteroid dehydrogenase type 1 activity in rodent adipocytes. J Endocrinol 2009;202: 131-9.
34. Dieudonne MN, Leneveu MC, Giudicelli Y, Pecquery R. Evidence for functional estrogen receptors a and b in human adipose cells: regional specificities and regulation by estrogens. Am J Physiol Cell Physiol 2004;286:C655-61.
35. Anwar A, McTernan PG, Anderson LA, Askaa J, Moody CG, Barnett AH, Eggo MC, Kumar S. Site-specific regulation of oestrogen receptor-a and -b by oestradiol in human adipose tissue. Diabetes Obes Metab 2001;3:338-49.
36. Pedersen SB, Bruun JM, Hube F, Kristensen K, Hauner H, Richelsen B. Demonstration of estrogen receptor subtypes a and b in human adipose tissue: influences of adipose cell differentiation and fat depot localization. Mol Cell Endocrinol 2001;182:27-37.
37. Rogers NH, Perfield JW 2nd, Strissel KJ, Obin MS, Greenberg AS. Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity. Endocrinology 2009;150:2161-8.
38. Phillips GB, Jing T, Heymsfield SB. Does insulin resistance, visceral adiposity, or a sex hormone alteration underlie the metabolic syndrome? Studies in women. Metabolism 2008;57: 838-44.
39. Vegeto E, Vegeto E, Belcredito S, Etteri S, Ghisletti S, Brusadelli A, Meda C, Krust A, Dupont S, Ciana P, Chambon P, Maggi A. Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol. Proc Natl Acad Sci USA 2003;100:9614-9.
40. Zancan V, Santagati S, Bolego C, Vegeto E, Maggi A, Puglisi L. 17b-Estradiol decreases nitric oxide synthase II synthesis in vascular smooth muscle cells. Endocrinology 1999;140: 2004-9.
41. Maggi A, Cignarella A, Brusadelli A, Bolego C, Pinna C, Puglisi L. Diabetes undermines estrogen control of inducible nitric oxide synthase function in rat aortic smooth muscle cells through overexpression of estrogen receptor-b. Circulation 2003;108:211-7.
42. Cignarella A, Bolego C, Pelosi V, Meda C, Krust A, Pinna C, Gaion RM, Vegeto E, Maggi A. Distinct roles of estrogen receptor-a and b in the modulation of vascular inducible nitricoxide synthase in diabetes. J Pharmacol Exp Ther 2009;328: 174-82.
43. Riant E, Waget A, Cogo H, Arnal JF, Burcelin R, Gourdy P. Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology 2009; 150:2109-17.
44. Straub RH. The complex role of estrogens in inflammation. Endocr Rev 2007;28:521-74.
45. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. J Am Med Assoc 1999;282:2131-5.
46. Lakoski SG, Brosnihan B, Herrington DM. Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial. Am Heart J 2005;150:907-11.
47. Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B, Jialal I. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 2003;41:1358-63.
48. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538-54.
49. Bonds DE, Lasser N, Qi L, Brzyski R, Caan B, Heiss G, Limacher MC, Liu JH, Mason E, Oberman A, O'Sullivan MJ, Phillips LS, Prineas RJ, Tinker L. The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomized trial. Diabetologia 2006;49:459-68.
50. Kanaya AM, Herrington D, Wittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Connor E. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement study - a randomized, double-blind, placebo- controlled trial. Ann Intern Med 2003;138:1-9.
51. Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, Bassford T, Burke G, Torrens J, Howard BV. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2006;47:1175-87.
52. Szmuilowicz ED, Stuenkel CA, Seely EW. Influence of menopause on diabetes and diabetes risk. Nat Rev Endocrinol 2009;5:553-8.
53. Howard BV, Hsia J, Ouyang P, Van Voorhees L, Lindsay J, Silverman A, Alderman EL, Tripputi M, Waters DD. Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation 2004;110:201-6.
54. Ferrara A, Quesenberry CP, Karter AJ, Njoroge CW, Jacobson AS, Selby JV, Northern California Kaiser Permanente Diabetes Registry. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995-1998. Circulation 2003;107: 43-8.